Serious Illness Policy Terms, Definitions and Claims Likelihood in Ireland

Executive summary

Specified Illness Cover pays a lump sum on diagnosis of one of a defined set of conditions, subject to definitional severity thresholds and a short survival period. The five domestic providers differ less in the headline list of illnesses than in the precision and generosity of the contractual definitions and in a small number of structural features such as the survival period, notification window and territorial scope. These contractual differences are often more important to whether a claim is admissible than the marketed headline count of illnesses.

Triangulating independent Irish epidemiology with international actuarial population-incidence work consistently supports the following relative claim-likelihood ranking by illness heading:

Key findings

Cancer is the dominant cause of admissible claims by a wide margin. Independent Irish epidemiology shows approximately 24,200 invasive non-NMSC cancers per year with a lifetime risk of approximately 1 in 3 men and 1 in 4 women before age 75. International actuarial sources consistently put cancer at 39–54% of all critical illness claim counts.

The cardiovascular bundle ranks second. Confirmed STEMIs ran to 1,615 in 2024 (75% male), with the broader AMI estimate around 6,000 per year. Stroke admissions reached 6,461 in 2023 and have risen approximately 22% since 2013.

Stroke claim-likelihood is highly sensitive to definition wording. Royal London and Zurich admit a wider range of strokes than Aviva, Irish Life and New Ireland, which require permanent neurological deficit.

MS is a low-volume heading but disproportionately important at working ages. Incidence is 8.7 per 100,000 women and 3.3 per 100,000 men, concentrated at ages 20–45 — exactly when serious illness covers are most active.

No single provider has the most claimant-friendly wording on every heading. Advisers should map the policy choice to the client's personal medical risk profile rather than the headline count of illnesses.

Why disease incidence is not the same as admissible claims

Several wedges separate population incidence from admissible claims. ABI-style cancer definitions exclude carcinoma in situ and impose stage/Gleason carve-outs; stroke requires either permanent neurological deficit or specific scan-plus-duration evidence; heart attack requires troponin or imaging evidence of myocardial necrosis; CABG full-payment normally requires open-heart surgery; benign brain tumour requires either persisting neurological symptoms or surgical/radiosurgical treatment.

Each definitional constraint narrows the share of disease cases that produce a paid full claim. Where definitions vary between Irish insurers, the wedge varies too. The indicative CI-admissible share of population disease events is approximately: cancer 78%, heart attack 70%, stroke 55%, MS 80%, CABG/PCI 30%, benign brain tumour 25%.

Market and product overview

At-a-glance definition comparison

The matrix below summarises definition-level differences for the six headings that drive the great majority of serious illness claims. Bold text (✓) highlights the most claimant-friendly wording in each row. No single provider leads on every line.

Claim-admissibility heatmap

The heatmap below records the relative generosity of each insurer's wording on each heading. This is a comparative judgment of definition claimant-friendliness, not an estimate of claim probability.

Illness likelihood matrix

Per-heading deep dive

Cancer — excluding less advanced cases

Cancer is the dominant cause of admissible claims by a wide margin. NCRI records approximately 24,200 invasive non-NMSC cancers per year. GLOBOCAN/IARC records a cumulative risk of any cancer before age 75 of 36.0% in men and 28.5% in women. Ireland's cancer incidence is above the EU average for both sexes — lung cancer incidence in Irish women is 63% above the EU average.

The key wedge from population incidence to admissible claims: approximately 18% of registered Irish tumours are non-invasive, and another approximately 24% are non-melanoma skin cancers — together more than 40% of the headline registry count is excluded from typical full-payment cancer cover.

The most common practical issues are early-stage prostate cancer (Gleason 6 vs 7), in-situ breast cancer (DCIS — paid as partial under all five), low-stage bladder, low-stage thyroid, and CLL diagnosed at Binet 0 on a routine blood test. Royal London's 2025 wording expressly extends cover to myeloproliferative neoplasms, pseudomyxoma peritonei and Merkel cell cancer — conditions not explicitly included by the other four.

Heart attack — myocardial infarction of specified severity

The 2024 Irish Heart Attack Audit recorded 1,615 confirmed STEMIs — 75% in men, 25% in women. Total AMI (STEMI plus NSTEMI) is estimated at approximately 6,000 per year in Ireland, with NSTEMI now exceeding STEMI in incidence.

The most consequential definitional difference: Aviva and New Ireland require all of typical clinical symptoms, ECG changes and a numeric troponin rise. Royal London's 2025 wording and Zurich's current wording both accept new diagnostic imaging changes (cardiac MRI, echocardiogram with wall-motion abnormality) as an alternative to ECG, and neither specifies a numeric troponin threshold. For NSTEMI cases without classical chest pain — common in older women and people with diabetes — the more inclusive wordings are materially more likely to admit a claim.

Stroke — resulting in specified or permanent symptoms

NOCA INAS recorded 6,461 stroke patients in 2023, an 8% increase on 2022. Hospital-coded stroke admissions rose from 4,727 in 2013 to 5,789 in 2021 (+22.5%). Stroke is the second leading cause of acquired adult neurological disability in Ireland.

The wedge between population stroke incidence and admissible CI claims is large. TIAs, reversible deficits and silent strokes do not pay under any of the five wordings. Beyond that, the minimum symptom duration threshold differs materially:

Multiple sclerosis — with persisting symptoms

The first prospective Irish MS incidence study recorded 292 patients per year giving an age-standardised incidence of 6.0 per 100,000 — 8.7 per 100,000 in women and 3.3 per 100,000 in men — placing Ireland in the high-incidence northern-European cluster. More than 10,000 people live with MS in Ireland, typically diagnosed at ages 20–40.

MS is low-volume in absolute terms but concentrated in working-age females — precisely where serious illness covers are most active. The McDonald 2017 and 2024 diagnostic criteria allow earlier diagnosis, which tends to bring forward CI claims under the more claimant-friendly wordings. Royal London and Zurich (both with no minimum persistence period) are the most generous; Aviva and New Ireland (6 months) are the tightest.

Coronary artery bypass grafts and cardiac procedures

Irish PCI rates increased by approximately 34.5% between 2006 and 2020 — one of the largest increases across 16 countries — while CABG has declined. All five providers exclude PCI, angioplasty, stent insertion and laser treatment from full payment; each pays a partial benefit for PCI instead.

The two practical differentiators: whether the policy requires median sternotomy (Aviva and New Ireland) or accepts thoracotomy/mini-thoracotomy (Irish Life, Zurich) or any open bypass route (Royal London). For most clients the practical question is the partial cover for PCI, since CABG is becoming relatively rarer.

Benign brain tumour — resulting in symptoms or surgery

NCRI records approximately 480 primary brain tumours per year in Ireland, approximately 190 of which are benign or uncertain. Meningioma incidence has risen sharply with expanded MRI access, but imaging-detected asymptomatic meningiomas generally do not pay a full CI claim.

The critical differentiator: Royal London (07/2025) is the only one of the five whose deficit waiver applies only to surgical removal — stereotactic radiosurgery (Gamma Knife, CyberKnife) does NOT waive the deficit requirement for Royal London. For meningiomas in skull-base locations where radiosurgery is the preferred treatment, the four other providers (Aviva, Irish Life, New Ireland and Zurich) will pay on radiosurgery alone, while Royal London will require either persisting deficit or surgical removal.

Operational differentiators

Beyond illness definitions, several operational features differ across providers and can affect claims outcomes:

Adviser checklist

Frequently asked questions

Conclusions

Specified illness cover in Ireland is homogeneous in headline terms — all five providers cover most of the same major conditions and operate within similar exclusion frameworks. Where the five providers differ — and where adviser attention should be concentrated — is in the precise contractual definitions of the headings that drive the great majority of admissible claims.

The independent epidemiology is clear: cancer and the cardiovascular bundle dominate expected claims. The contractual wording determines what share of those events actually pays under each policy. The most consequential service an adviser can perform is to read the verbatim definition for the heading that matters most to the individual client. Headline counts of "52" or "70" illnesses say very little about whether a future event will pay a full claim; the wording does.